Page 32 - FiM_03_2016

ABSTRACT
PET scanner Clinical Trial Qualification for onco-haematological studies: inter scanner variability with 18F and 68Ge phantom.
Candidato: Fabrizio Bergesio
Relatore: Stéphane Chauvie
Azienda Ospedaliera Santa Croce e Carle Cuneo
Scuola di Specializzazione in Fisica Medica (A.A. 2014-2015) Direttore: Roberto Cirio
INTRODUCTION
Positron Emission Tomography/Computed Tomography (PET/CT) imaging is increasingly used in oncology, for the diagnosis, staging and assessment of treatment response. The most commonly tracer for oncology is 18F-fluoro-2-deoxy-D-glucose (18F-FDG), a glucose analogue that has been applied in lung, head and neck, prostate, cervical, colorectal, lymphoma, melanoma and breast cancers.
Two basic approaches can be considered for assessing the metabolic changes of treatment: qualitative and quantitative. An issue is whether a response scale should be binary (yes/no for response) or continuous (giving varying degrees of response).
The principal limit for using of the quantitative parameters is the error that it associated to the measure. In clinical routine it is possible consider an error of 20-50% associated to the SUV measurements. Several factors affects that parameters, some are related to the patients, others to the protocol of acquisition and others depends from the PET/CT scanner.
Since scanners give different quantitative readings, a program for clinical trial qualification (CTQ) is mandatory to guarantee a reliable and reproducible use of quantitative PET in prospective multi- centre clinical trials and in every-day clinical life.
MATHERIALS & METHODS
The Cuneo Corelab set-up a CTQ program consisting on the PET/CT scan acquisition and analysis of two 18F phantoms, uniform (UQP) and image quality (IQ) phantoms, and a new 68Ge NEMA/IEC image quality phantoms for the reduction of inter-scanner variability (ISV) defined as the 95% C.I.
Tesi di Specialità
24